Skip to main content

ASCPT 2023 Annual Meeting Main banner

Tweets by ASCPT 2023 Annual Meeting

Browse by Poster Title

Browse by Poster Title

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#

E
PI-059
EARLY CLINICAL PK/PD MODELING AND SIMULATION OF ALPN-303, A POTENT DUAL BAFF/APRIL ANTAGONIST, TO SUPPORT FIRST-IN-DISEASE CLINICAL TRIALS IN SYSTEMIC LUPUS ERYTHEMATOSUS AND OTHER B CELL-RELATED DISEASES.

Favorite
PII-006
EARLY PHARMACODYNAMIC BIOMARKER DEVELOPMENT IN ADOLESCENTS WITH EATING DISORDERS.

Favorite
PI-060
ECULIZUMAB COMPLEMENT-MEDIATED PK/PD MODEL-INFORMED SIMULATIONS REVEAL THE NEED FOR ALTERNATIVE DOSING REGIMENS DURING MAINTENANCE THERAPY FOR STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (TA-TMA).

Favorite
PI-061
EFFECT OF A MODERATE CYP3A4 INDUCER ON ENCORAFENIB IN COMBINATION WITH BINIMETINIB IN PATIENTS WITH BRAF V600-MUTANT UNRESECTABLE OR METASTATIC MELANOMA OR OTHER ADVANCED SOLID TUMORS.

Favorite
PI-062
EFFECT OF ACT-539313, A SELECTIVE OREXIN-1 RECEPTOR ANTAGONIST, ON THE CYTOCHROME P450 2C9, 2C19, AND 3A4 SUBSTRATES FLURBIPROFEN, OMEPRAZOLE, AND MIDAZOLAM USING A COCKTAIL APPROACH.

Favorite
PII-054
EFFECT OF COMPLEMENT FACTOR 5A RECEPTOR 1 (C5AR1) ANTAGONIST ACT-1014-6470 ON THE CYTOCHROME P450 2C19 AND 3A4 SUBSTRATES OMEPRAZOLE AND MIDAZOLAM IN A COCKTAIL STUDY IN HEALTHY SUBJECTS.

Favorite
PI-026
EFFECT OF CYP2D6 PHENOTYPE ON PHARMACOKINETICS OF DWN12088, A NOVEL PROLYL-TRNA SYNTHETASE INHIBITOR, IN A FIRST-IN HUMAN STUDY.

Favorite
PI-063
EFFECT OF CYP3A AND CYP2D6 GENOTYPES ON THE PHARMACOKINETICS OF OXYCODONE IN CHILDREN.

Favorite
PWIII-004
EFFECT OF CYP3A AND CYP2D6 GENOTYPES ON THE PHARMACOKINETICS OF OXYCODONE IN CHILDREN.

Favorite
PI-027
EFFECT OF GENETIC VARIANTS IN TSPYL ON THE PHARMACOKINETICS OF CYCLOSPORINE.

Favorite
PI-016
EFFECT OF MILD AND MODERATE HEPATIC IMPAIRMENT ON QUIZARTINIB PHARMACOKINETICS.

Favorite
E-001
EFFECT OF PAROXETINE OR QUETIAPINE COMBINED WITH OXYCODONE VS OXYCODONE ALONE ON VENTILATION DURING HYPERCAPNIA: A RANDOMIZED CLINICAL TRIAL.

Favorite
PII-122
EFFECT OF THE CHOLESTYRAMINE-INDUCED ALTERATION OF BILE ACID POOL IN THE GUT ON THE PHARMACODYNAMICS OF METFORMIN: AN EXPLORATORY STUDY.

Favorite
LB-016
EFFECTIVENESS OF HIGH DOSE VERSUS STANDARD DOSE INFLUENZA VACCINES IN OLDER ADULTS : INSIGHTS FROM A MULTI-STRAIN MODELING APPROACH TAKING ANTIGENIC DISTANCE INTO ACCOUNT.

Favorite
LB-006
EFFECTS OF ANTIOXIDANTS IN DRUGS PRODUCTS ON INTESTINAL DRUG TRANSPORTERS.

Favorite
PI-064
EFFECTS OF GLPG3970 ON SULFASALAZINE AND METHOTREXATE PHARMACOKINETICS IN HEALTHY ADULTS: RESULTS OF TWO OPEN-LABEL, PHASE I, DRUG–DRUG INTERACTION STUDIES.

Favorite
PI-081
ELEXACAFTOR/TEZACAFTOR/IVACAFTOR (ETI) -INDUCED REACTIVE OXYGEN SPECIES (ROS) PRODUCTION IN HEPG2 CELLS: A POTENTIAL MECHANISM OF DRUG-INDUCED LIVER INJURY (DILI)

Favorite
PI-017
ELIGIBILITY CRITERIA OF EARLY PHASE ONCOLOGY TRIALS.

Favorite
EP-036
ESTIMATING TARGET ENGAGEMENT USING SINGLE POST-DOSE TIMEPOINT TO SUPPORT FURTHER CLINICAL DEVELOPMENT.

Favorite
EP-014
ESTIMATION OF NOVEL BISPECIFIC T-CELL ENGAGER (BiTE®) MOLECULE PHARMACOKINETICS IN CYNOMOLGUS MONKEY FROM STRUCTURALLY-SIMILAR BiTE MOLECULE DATA.

Favorite
PI-066
ETEPLIRSEN, GOLODIRSEN, AND CASIMERSEN SHOW CONSISTENT CLINICAL PHARMACOLOGY PROPERTIES FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY.

Favorite
LB-012
ETHANOL AS AN EXCIPIENT IN DRUG FORMULATIONS ADMINISTERED TO NEONATES: PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING TO INFORM SAFETY.

Favorite
PI-103
EVALUATING THE CONSISTENCY AND EXTENT OF IMMUNOGENICITY REPORTING FOR RECENTLY APPROVED BIOLOGICS.

Favorite
PWIII-005
EVALUATING THE IMPACT OF PROTON PUMP INHIBITOR USE ON CARDIOVASCULAR OUTCOMES IN PATIENTS RECEIVING CYP2C19 GENOTYPE GUIDED ANTIPLATELET THERAPY IN A REAL-WORLD SETTING.

Favorite
PI-028
EVALUATING THE IMPACT OF PROTON PUMP INHIBITOR USE ON CARDIOVASCULAR OUTCOMES IN PATIENTS RECEIVING CYP2C19 GENOTYPE GUIDED ANTIPLATELET THERAPY IN A REAL-WORLD SETTING.

Favorite
EP-028
EVALUATING THE UTILITY OF PROTEOMICS FOR THE IDENTIFICATION OF CIRCULATING PHARMACODYNAMIC BIOMARKERS OF IFNΒ-1A BIOLOGICS.

Favorite
PI-067
EVALUATION OF CREATININE-BASED RENAL FUNCTION ESTIMATION EQUATIONS BY PHARMACOMETRIC ANALYSIS FOR ANTIBIOTICS.

Favorite
PII-111
EVALUATION OF SEX DIFFERENCES IN MEDICATION PRESCRIBING RECOMMENDATIONS AND OCCURRENCE OF ADVERSE EVENTS.

Favorite
PI-029
EVALUATION OF THE G6PD VARIANT C.376A>G ACTIVITY IN ALL OF US.

Favorite
EP-027
EXAMINING THE REGIONAL IMPACT OF FENTANYL ON INFLAMMATORY MEDIATORS WITHIN THE BRAIN IN THE SETTING OF HIV.

Favorite
PII-007
EXPERIENCES OF CEREBROSPINAL FLUID COLLECTION, EITHER BY SERIAL SAMPLING OR BY LUMBER PUNCTURES, IN CLINICAL PHARMACOLOGY RESEARCH.

Favorite
EP-015
EXPLAINING INTERPATIENT VARIABILITY OF ADALIMUMAB RESPONSE IN CHRONIC PLAQUE PSORIASIS BY PHARMACOKINETIC-PHARMACODYNAMIC MODELLING: RESULTS FROM THE OPTIMAP STUDY.

Favorite
PI-084
EXPLORATION FOR EXCLUSION OF FEMALES OF REPRODUCTIVE POTENTIAL AS A BIOEQUIVALENCE STUDY POPULATION IN PRODUCT-SPECIFIC GUIDANCES FOR GENERIC DRUG DEVELOPMENT.

Favorite
PWIV-001
EXPLORATION FOR EXCLUSION OF FEMALES OF REPRODUCTIVE POTENTIAL AS A BIOEQUIVALENCE STUDY POPULATION IN PRODUCT-SPECIFIC GUIDANCES FOR GENERIC DRUG DEVELOPMENT.

Favorite
PI-068
EXPOSURE-RESPONSE (E-R) OF DUPILUMAB IN PAEDIATRIC PATIENTS WITH MODERATE-TO-SEVERE ASTHMA.

Favorite
PI-069
EXPOSURE-RESPONSE MODELING STRATEGIES IN ONCOLOGY: IMPACT OF DOSE REDUCTIONS ON INTERPRETATION OF RESULTS.

Favorite
PI-070
EXPOSURE-TARGETED MELPHALAN DOSING INDIVIDULIZATION IN PATIENTS WITH MULTIPLE MYELOMA UNDERGOING AUTOLOGOUS TRANSPLANT.

Favorite
PT-003
EXPRESSION OF ABCB1 IS DECREASED IN PLACENTA OF WOMEN WITH AUTOIMMUNE DISEASE AND IN CYTOKINE- TREATED PLACENTAL EXPLANTS.

Favorite
E-004
EXTRAPOLATION OF EFFICACY OF A DEXTROAMPHETAMINE TRANSDERMAL SYSTEM (d-ATS) FROM PEDIATRIC (PED) TO ADULT POPULATIONS USING PHARMACOKINETIC (PK) MODELING.

Favorite